Literature DB >> 11501617

Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin.

E S Rovner1, A J Wein.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11501617     DOI: 10.1046/j.1464-410x.2000.00097.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  5 in total

1.  Selecting a medical therapy for overactive bladder.

Authors:  H Henry Lai; Timothy B Boone; Rodney A Appell
Journal:  Rev Urol       Date:  2002

Review 2.  Update on overactive bladder: pharmacologic approaches on the horizon.

Authors:  Eric S Rovner; Alan J Wein
Journal:  Curr Urol Rep       Date:  2003-10       Impact factor: 3.092

3.  Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.

Authors:  R Altan-Yaycioglu; O Yaycioglu; Y Aydin Akova; S Guvel; H Ozkardes
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

4.  Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system.

Authors:  R Howard Zobrist; Danyi Quan; Heather M Thomas; Stephanie Stanworth; Steven W Sanders
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

Review 5.  Pharmacologic treatment for detrusor overactivity.

Authors:  H Henry Lai; Timothy B Boone; Rodney A Appell
Journal:  Curr Urol Rep       Date:  2002-10       Impact factor: 2.862

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.